Main Therapeutic Uses

Butapirazol is a medication primarily utilized for its analgesic and anti-inflammatory properties. It belongs to the pyrazolone class of drugs and is indicated for the management of severe inflammatory and painful conditions that have not responded to other treatments.

Inflammatory Joint Diseases

The medication is most commonly used to address chronic inflammatory disorders of the musculoskeletal system. These include:

• Rheumatoid Arthritis: To help manage the persistent inflammation and pain associated with the joints.
• Ankylosing Spondylitis: To alleviate the spinal stiffness and inflammatory pain characteristic of this condition.
• Osteoarthritis: Used during acute flare-ups when severe pain and inflammation are present.

Acute Gouty Arthritis

Butapirazol is effective in treating the intense pain and localized inflammation caused by acute gout attacks. It helps reduce the swelling and tenderness in the affected joints, typically starting with the large toe or lower limbs.

Soft Tissue Disorders

Beyond bone and joint conditions, the medication is also used for various inflammatory states affecting soft tissues, such as:

• Bursitis: Inflammation of the fluid-filled sacs that cushion the joints.
• Tendinitis: Inflammation of the tendons resulting from injury or overuse.
• Thrombophlebitis: Inflammation of a vein related to a blood clot, where the medication is used to reduce localized pain and swelling.

Therapeutic Benefits

The primary benefit of Butapirazol is the reduction of prostaglandin synthesis, which are the chemical messengers responsible for signaling pain and promoting inflammation in the body. By inhibiting these processes, the medication provides:

• Pain Relief: Significant reduction in moderate to severe pain levels.
• Inflammation Control: Decrease in redness, heat, and swelling at the site of injury or disease.
• Improved Mobility: By reducing pain and stiffness in the joints, it may help restore a degree of physical function during acute inflammatory episodes.

Regulatory References

1. Health Canada Product Monograph

Who Can and Cannot Use Butapirazol?

Official regulatory information strictly defines the eligible population for Butapirazol (Phenylbutazone) by establishing a series of absolute contraindications and population restrictions. The medicine is generally limited to adult patients who do not have any specific pre-existing conditions.

---

Populations For Whom Use is Contraindicated

Use is prohibited for individuals with several serious comorbidities, as documented in official labeling:

• Patients with active gastrointestinal ulceration or bleeding.
• Individuals suffering from severe cardiac, hepatic, or renal dysfunction.
• Patients with blood dyscrasias or a known haemorrhagic diathesis.
• Any person with a confirmed hypersensitivity to Phenylbutazone or other NSAIDs.

---

Age and Reproductive Restrictions

• Pediatric Use: The medication is contraindicated in children fourteen years of age or less.
• Geriatric Use: Use is contraindicated in senile patients.
• Pregnancy and Lactation: Use is not recommended during either pregnancy or breastfeeding.

---

These mandated regulatory rules determine the authorized user population and strictly limit the use of this medicine based on a patient's medical history and current physiological status.

Interaction Map: Interactions with other medicines and products — official regulatory information for Butapirazol

---

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions:	Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Coumarin Anticoagulants, Corticosteroids, Diuretics, Highly Protein-Bound Drugs, Nephrotoxic Drugs.
Mechanistic basis of interactions (only if stated in label):	Competition at plasma protein binding sites, reduced metabolism of co-administered drugs, inhibition of renal prostaglandin synthesis.
Timing-based interaction rules (if applicable):	Mandatory separation of at least 24 hours between the administration of Butapirazol and other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
Population-specific interaction notes (if applicable):	Interaction severity is officially noted as elevated in patients with existing serious hepatic, renal, or cardiac pathology.
Interaction-related restrictions:	Contraindicated or strongly advised to avoid concurrent administration with other NSAIDs and potentially nephrotoxic drugs. Use with substantial quantities of Ethanol (Alcohol) may increase the risk of hepatotoxicity.

---

Interaction Classifications (High-Level)

Classification Type	Official Regulatory Documentation
Interaction severity classification (as defined in official documents):	Contraindicated combinations (e.g., other NSAIDs), Clinically significant interactions (e.g., Anticoagulants), Potentiation of effects, Reduction of efficacy.

---

Resulting Interaction Structure

Official interaction statements:

• Butapirazol amplifies the anticoagulant effect of Coumarin Anticoagulants, which increases the risk of serious bleeding complications.
• It may elevate and prolong serum levels of co-administered drugs such as Methotrexate and Phenytoin due to reduced clearance.
• Co-administration with highly protein-bound agents, such as Sulfonamides, results in competition at binding sites, increasing the free active plasma concentration of the co-administered drug.
• The efficacy of diuretics is officially documented as reduced due to interference with renal prostaglandin synthesis.

Connection to the overall interaction profile (3 sentences): Regulatory documents define the product's interaction structure primarily through its capacity to increase the active exposure of co-administered drugs via protein binding displacement and metabolic interference. The profile also includes official warnings regarding additive pharmacodynamic toxicity, such as increased gastrointestinal and renal risks. Consequently, the regulatory information imposes explicit contraindications and mandatory timing rules to mitigate these documented interaction patterns.

Molecular Mechanism: Non-Selective Enzyme Inhibition

The active substance, Phenylbutazone, begins its action by non-selectively inhibiting the Cyclooxygenase (COX) enzymes, both COX-1 and COX-2. This molecular intervention effectively blocks the conversion of arachidonic acid into various prostaglandin molecules. This initial molecular step modulates the subsequent generation of lipid mediators in multiple physiological responses.

---

️ Systemic Effect: Modulating Inflammatory and Nociceptive Pathways

The primary mechanistic consequence of COX inhibition is the widespread reduction of prostaglandin synthesis, which modulates the biochemical signals sustaining inflammatory processes. This reduction decreases the sensitivity of peripheral nerve endings (nociceptors) and modifies the local vasodilation and vascular permeability associated with fluid accumulation in tissues.

---

️ Central Effect: Regulation of Thermoregulation

A distinct part of the drug's mechanism involves its activity in the brain, specifically within the hypothalamus. By inhibiting COX activity there, the drug modulates the signaling pathway that maintains an elevated core temperature.

How to Use Butapirazol

Butapirazol (Phenylbutazone) administration follows a structured protocol focusing on the route, dosing pattern, and time-limited use. The medication is available in several dosage forms, including tablets for oral use, solutions for intravenous injection, and oral preparations like powders.

---

Administration and Dosing Schedule

The sequence for use involves a specific progression. Treatment typically begins with a relatively high initial dose administered over the first 48 hours to initiate a therapeutic level. This initial dose is then gradually reduced to achieve the lowest possible effective maintenance dosage. Administration may follow a daily schedule or be used intermittently during symptomatic episodes.

Administration Constraint	Implementation Principle
Route Restriction	Parenteral administration is restricted to the intravenous route only and must be performed slowly.
Duration Limit	Intravenous use is generally limited to a maximum of five successive days.
Response Check	Treatment is discontinued if no significant clinical response is achieved after four to five days.

---

Population-Specific Use

For older adults or frail patients, the protocol specifies the use of a lower-than-usual starting dose and requires subsequent adjustments to be made under close supervision. This ensures that the application is adjusted to the individual's context while following the fundamental principles of initial reduction and minimal effective dosing. Oral powder forms are administered mixed with palatable feed.

Efficacy and Quality of Life (QoL)

Research has evaluated whether the Quality of Life (QoL) for patients with Chronic Migraine (CM) was designed to evaluate QoL outcomes when administered for 12 weeks. Multiple studies examined a possible change in pain frequency and severity in patients with Episodic Migraine (EM).

One large-scale Phase 3 trial, known as Study 456, reported findings related to a reduction in the number of monthly migraine days (MMDs). Study results indicated that a reduction in MMDs was observed for up to six months post-treatment.

---

Comparative Studies

For the prevention of migraine, research has explored whether the combination might impact outcomes compared with either agent alone. Studies have explored whether the proposed action is associated with quick response in acute settings, particularly in individuals who experience frequent, debilitating attacks.

---

Safety Profile in Special Populations

For older adults, research has examined potential risks associated with long-term use, including cardiovascular issues. Overall, clinical data reported findings on the incidence of adverse events (AEs), which were observed across a range of severity across all study groups.

Key Studies & References

1. Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review (Source for general migraine background and safety profile context for older treatments)

Butapirazol (Phenylbutazone) must be stored according to specific regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

Store the medication at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture and excessive heat and should not be frozen. Keep the medication in its original container and ensure the container is tightly closed when not in use. As with all medicines, store Butapirazol out of the sight and reach of children to prevent accidental ingestion.

---

Disposal Instructions

Dispose of any unused or expired Butapirazol strictly according to local regulations and official governmental guidance. Utilize a community drug take-back program if one is available. The medication should not be flushed down a toilet or sink, and must not be disposed of via wastewater.